Mal-Propionyl-Beta-Ala-Val-Cit-PAB(m-PEG8)-PNP Thalidomide 562 SMILES: OC1=CC2=C(C=C1)C1(OC(=O)C3=CC(=CC=C13)C(=O)NCCOCCOCCOCCN=[N]#N)C1=CC=C(O)C=C1O2

562 SMILES: OC1=CC2=C(C=C1)C1(OC(=O)C3=CC(=CC=C13)C(=O)NCCOCCOCCOCCN=[N]#N)C1=CC=C(O)C=C1O2

609 SMILES OC(=O)CN1CCN(CC(O)=O)CCN(CC(=O)NCCOCCOCCN=[N+]=[N-])CCN(CC(O)=O)CC1 Purity (HPLC) >= 95% Shipping Conditions Room temperature Storage Conditions Refrigerated Shelf Life 12 months after the date of delivery Regulatory Statement For Research Use Only

5-(and-6)-carboxy-2

Product Name Thalidomide-O-acetamido-PEG3-C2-Br Synonyms Thalidomide-4'-O-acetamido-PEG3-C2-Br CAS Number n/a Related CAS Molecular Formula C23H28BrN3O9 Molecular Weight 570

BCN (bicyclo[6

Mal-Propionyl-Beta-Ala-Val-Cit-PAB(m-PEG8)-PNP Thalidomide 562 SMILES: OC1=CC2=C(C=C1)C1(OC(=O)C3=CC(=CC=C13)C(=O)NCCOCCOCCOCCN=[N]#N)C1=CC=C(O)C=C1O2SOLU KNEX cleavable linker features a Val Cit dipeptide. In this product, m PEG8 is attached to the commonly used self immolative para aminobenzyl (PAB) moiety to increase aqueous solubility. The PNP (para nitrophenyl) moiety serves as an activating leaving group, enabling efficient and selective conjugation of the payload to the linker. Derived from established ADC linker architectures, SOLU KNEX ADC linkers integrate solubilizing moietiessuch as